June 4, 2019

Glytec Developing Novel Solution for Selection and Dosing of All Diabetes Medications

New product will be the market’s first and only to enable optimization of ALL diabetes medications, insulin and non-insulin alike.

In spite of greater than 80 medications currently available in the U.S. to treat diabetes, less than half of the estimated 22 million people prescribed one or more are maintaining blood sugar levels within the acceptable range. The consequences not only impact health status and quality of life, they add to the growing economic burden of diabetes estimated in 2017 at $327 billion. With multiple patent allowances for its novel Therapy Advisor® software-as-a-medical-device and active engagement in the FDA 510(k) process, Glytec is poised to improve these clinical and financial outcomes by helping providers more easily and efficaciously select and dose all varieties of diabetes medications. No solution of like kind is currently available, Therapy Advisor® will be the first.

October 30, 2018

Glytec publishes free eBook: Hypoglycemia in the hospital. Why is it costing you millions and what can you do?

The popular eBook showcases clinical and financial implications of hypoglycemia, a common occurrence among hospitalized patients that costs the average hospital $1.5 to $5.6 million a year, or more.

Hypoglycemia in the hospital is common, costly, extremely serious and largely preventable, but many c-suite and business office executives are unaware of what it is, why it occurs or the significant impact it has on patient safety, outcomes and economics. A new eBook from Glytec, offered free of charge at the company’s website, shines a light on critical concerns surrounding hypoglycemia and helps healthcare organizations understand how to mitigate risks and initiate optimal prevention strategies. Availability of the eBook is especially timely given the hypoglycemia quality measure currently under development by the Centers for Medicare & Medicaid Services (CMS).

July 24, 2017

Robby Booth of Glytec Discusses the Importance of Data-Sharing Capabilities

Data-sharing capabilities are important for faster communications and results that can greatly benefit the patient, says Robby Booth, senior vice president of research and development at Glytec.

Over the past few months, there have been some announcements that we’ve made. We have a partnership now with AgaMatrix, which is a Bluetooth glucose meter, to be able to capture their data from the cloud. We have a partnership with Livongo, which is a cellular meter, so we can capture that data from their cloud; and we have a partnership with Telcare, which is also a cellular meter.

July 20, 2017

Dr. Andrew Rhinehart: Improving Intermediate Outcomes in Diabetes Research

Andrew Rhinehart, MD, chief medical officer at Glytec, discusses the transition from intermediate outcomes in diabetes research of glycemic results to harder outcomes that will benefit the patient financially and through their care.

Over the last year or so, we’ve made a concerted effort to switch our evidence strategy from that of solely glycemia control to one of the hard outcomes. We call the glucose control more of an intermediary outcome, and we know that we can reduce hypoglycemia in hospitals, and we know that we can reduce hyperglycemia, and keep people in that glucose target range more frequently.

April 10, 2017

Advancements in Diabetes Treatment to Watch

The healthcare industry continues to focus efforts on treatments that work better, and ideally are less expensive and less invasive for patients.

Diabetes therapy management software with decision support for dosing and titration is the final piece of the therapeutic puzzle. In concert with data made available through CGM and cBGM, this software can help providers properly dose and titrate diabetes medications, especially insulin, and choose which diabetes medications may work best for each patient. Diabetes therapy management software, in its earliest form, was launched by Glytec in 2006.

January 27, 2017

Diabetes Management Software from Glytec Automates Insulin Dosing Support

Glytec’s cloud-based software system provides personalized therapy and management for acute diabetes and hypoglycemia patients to help providers meet goals for value-based care.

Each month, the editors at SearchHealthIT recognize an innovative software, service or technology approach. Glytec’s diabetes management software system is our January 2017 selection.

October 6, 2016

Glytec Named Fierce Innovation Awards Finalist, Healthcare Edition, for Precision Diabetes Management Solution

The awards competition shines a light on the company’s patented eGlycemic Management System®, or eGMS®.

FierceMarkets, the publisher of FierceHealthcare, FierceHealthIT and FierceHealthPayer, has named Glytec a finalist in the 2016 annual Healthcare Edition of its Fierce Innovation Awards program. One of the primary goals of the program is, ‘To identify and reward the fiercest, most evolutionary technologies and services that can transform healthcare delivery and operational success.’

November 1, 2010

Glytec Insulin Dosing Software Now Compatible with BlackBerry, Android, and iPhone

The G+ Enterprise Edition software is now compatible with select Android, BlackBerry, and iPhone devices, including the new iPhone 4 and iPad.

Glytec, LLC, a leader in glycemic management solutions, announced today that it has released a new enhancement to its inpatient blood glucose management software. The G+ Enterprise Edition software provides both intravenous and subcutaneous dosing recommendations of insulin and glucose and can be accessed from any computer within a hospital’s network. Users with mobile devices can now access real-time patient information, allowing for better monitoring of insulin dosing and blood glucose levels.